A Combination Approach for Treatment of Castration-Resistant Prostate Cancer
Technical Report,01 Sep 2015,31 Aug 2016
ADMINISTRATORS OF THE TULANE EDUCATIONAL New Orleans United States
Pagination or Media Count:
Abiraterone, enzalutamide, and taxanes are first-line treatments for metastatic castration-resistant prostate cancer mCRPC. They prolonged overall survival of the patients. However, both de novo and acquired resistance are common. Accumulating evidence has indicated a role of androgen receptor splice variants AR-Vs in mediating resistance to these therapies. The purpose of this study is to develop 20S-protopanaxadiol-aglycone PPD, which we showed to downregulate the levels and activities of AR-Vs, as an antidote to overcome resistance to these therapies. We showed that PPD might attenuate AR-V homodimerization and that combined treatment with PPD and enzalutamide might be more efficacious than enzalutamide alone in inhibiting the growth of CRPC tumors.
- Medicine and Medical Research